Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences - PubMed (original) (raw)
Review
Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences
Wolf-Henning Boehncke. Front Immunol. 2018.
Abstract
Psoriasis is a common inflammatory skin disease characterized by the appearance of red scaly plaques that can affect any part of the body. High prevalence, chronicity, disfiguration, disability, and associated comorbidity make it a challenge for clinicians of multiple specialties. Likewise, its complex pathogenesis, comprising inflammation, hyperproliferation, and angioneogenesis, intrigues numerous scientific disciplines, namely, immunology. From a clinical perspective, the severity of psoriasis is highlighted by its increased mortality, with cardiovascular diseases contributing the highest excess risk. From a scientific point of view, psoriasis has to be considered a systemic inflammatory condition, as blood biomarkers of inflammation are elevated and imaging techniques document sites of inflammation beyond the skin. While the association of psoriasis with cardiovascular diseases is now widely accepted, causes and consequences of this association are controversially discussed. This review comments on epidemiologic, genetic, and mechanistic studies that analyzed the relation between psoriasis and cardiovascular comorbidity. The hypothesis of psoriasis potentially being an independent cardiovascular risk factor, driving atherosclerosis via inflammation-induced endothelial dysfunction, will be discussed. Finally, consequences for the management of psoriasis with the objective to reduce the patients' excess cardiovascular risk will be pointed out.
Keywords: atherosclerosis; coronary heart disease; endothelial dysfunction; insulin resistance; mortality; psoriasis; stroke.
Figures
Figure 1
Metabolic and vascular effects of insulin. Under physiologic conditions, the activated insulin receptor on endothelial cells leads to phosphorylation of endothelial nitric oxide synthase (eNOS) via activation of insulin receptor substrate (IRS) and phosphoinositide-3-kinase (a). This results in vasodilation via NO production. This branch also regulates GLUT4 translocation and glucose uptake in muscle cells. The mitogen-activated protein kinase (MAPK) pathway controls secretion of vasoconstrictive ET-1 in endothelial cells, and cell growth and mitogenesis in cells at large. Inflammation reduces NO production via blocking insulin receptor signaling at the level of the IRS-1 (b).
Figure 2
The concept of the “psoriatic march.” This hypothesis suggests that psoriasis is a systemic inflammatory condition, as numerous biomarkers of inflammation are elevated in the patients’ blood compartment. Functional consequences are insulin resistance, evidenced by an increased HOMA-IR (homeostasis assessment of insulin resistance), and endothelial dysfunction, resulting in increased vascular stiffness. This provides the basis for atherosclerosis, observable through analysis of vessel wall composition via CTs or ultrasound. Depending on the sites of atherosclerosis, major cardiovascular events such as myocardial infarction and stroke result from this. This “backbone” (red, bold) may be developed further by adding additional “modules”: insulin resistance has been shown to alter epidermal homeostasis (red, fine). Obesity, causing a state of systemic inflammation as well, is a known risk factor for psoriasis and may induce the phenotype (orange, bold). Whether systemic anti-inflammatory therapy is capable of reducing the patients’ cardiovascular risk through reducing insulin resistance and endothelial dysfunction is still a matter of debate (green).
Similar articles
- Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives.
Kapniari E, Papadimitriou P, Dalamaga M, Makavos G, Piaserico S, Egeberg A, Ikonomidis I, Papadavid E. Kapniari E, et al. Curr Vasc Pharmacol. 2020;18(6):592-609. doi: 10.2174/1570161118666200523154318. Curr Vasc Pharmacol. 2020. PMID: 32445456 Review. - Psoriasis and cardiovascular disorders.
Frieder J, Ryan C. Frieder J, et al. G Ital Dermatol Venereol. 2016 Dec;151(6):678-693. Epub 2016 Sep 14. G Ital Dermatol Venereol. 2016. PMID: 27627099 Review. - Psoriasis: a skin disease associated with increased cardiovascular risk.
González-Gay MA, González-Vela C, González-Juanatey C. González-Gay MA, et al. Actas Dermosifiliogr. 2012 Sep;103(7):595-8. doi: 10.1016/j.ad.2012.01.006. Epub 2012 Mar 31. Actas Dermosifiliogr. 2012. PMID: 22465257 Review. English, Spanish. - The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity.
Boehncke WH, Boehncke S, Tobin AM, Kirby B. Boehncke WH, et al. Exp Dermatol. 2011 Apr;20(4):303-7. doi: 10.1111/j.1600-0625.2011.01261.x. Exp Dermatol. 2011. PMID: 21410760 - [Psoriasis, a systemic disease?].
Puig-Sanz L. Puig-Sanz L. Actas Dermosifiliogr. 2007 Jul-Aug;98(6):396-402. Actas Dermosifiliogr. 2007. PMID: 17663929 Review. Spanish.
Cited by
- Nailfold Capillaroscopy Findings in Patients With Psoriasis Vulgaris and Different Domains of Psoriatic Arthritis.
Elmesiry AM, Mahmoud SA, Mohamed MS, Aly H, Elmotaleb YA, Ghit MM, Ibrahim AS, Elazab SA, Mokhtar M, Rageh EA, Moussa MA, Ismail S, El Zokm SM, Hamoud H. Elmesiry AM, et al. J Psoriasis Psoriatic Arthritis. 2024 Jul;9(3):89-97. doi: 10.1177/24755303241238988. Epub 2024 Mar 15. J Psoriasis Psoriatic Arthritis. 2024. PMID: 39301215 - Characteristics of Patients With Psoriasis Treated With Various Biologics - A Danish Cohort Study.
Schwarz CW, Skov L, Egeberg A, Passey A, Lee J, Gorecki P, Loft N. Schwarz CW, et al. J Psoriasis Psoriatic Arthritis. 2024 Apr;9(2):51-60. doi: 10.1177/24755303241234292. Epub 2024 Feb 19. J Psoriasis Psoriatic Arthritis. 2024. PMID: 39301091 - Can Serum Fetuin-A be Used as a Marker for Cardiovascular Involvement in Psoriatic Patients?
Saleh HM, Sheha AS, Eskander NN, Elhawatky AF, Hassen SI. Saleh HM, et al. J Psoriasis Psoriatic Arthritis. 2023 Apr;8(2):66-73. doi: 10.1177/24755303221135570. Epub 2023 Feb 15. J Psoriasis Psoriatic Arthritis. 2023. PMID: 39296671 Free PMC article. - Do interleukin-17 and interleukin-23 inhibitors alter the coagulation parameters in psoriasis patients?: A retrospective study.
Ünal S, Yüksek T, Öğüt ND, Yıldırım SK, Erbağcı E, Gökyayla E. Ünal S, et al. Arch Dermatol Res. 2024 Sep 11;316(8):613. doi: 10.1007/s00403-024-03369-3. Arch Dermatol Res. 2024. PMID: 39259347 - Unbiased Proteomic Exploration Suggests Overexpression of Complement Cascade Proteins in Plasma from Patients with Psoriasis Compared with Healthy Individuals.
Kromann B, Niu L, Møller LBP, Sølberg J, Sulek K, Gyldenløve M, Dyring-Andersen B, Skov L, Løvendorf MB. Kromann B, et al. Int J Mol Sci. 2024 Aug 13;25(16):8791. doi: 10.3390/ijms25168791. Int J Mol Sci. 2024. PMID: 39201477 Free PMC article.
References
- WHO. Document EB133.R2, Agenda Item 6.2. (2013).
- Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol (2011) 147(9):1031–9.10.1001/archdermatol.2011.119 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical